David Zaccardelli, Verona CEO
Two years after flop, Verona gets a win as it preps for pivotal Phase III trials
Two years after the lead formulation of Verona’s lead COPD drug whiffed in a Phase II study that knocked back their stock, another formulation …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
